Gx™ Inherited Cancer Risk Gene Testing

Analyzes 39 genes linked to breast, ovarian, colorectal, pancreatic, and other major types of cancers

Gx™ Inherited Cancer Gene Testing (Gx™ InhCa)

Early cancer screen contributes to greatly increased life expectancy in the US, according to a recent report in JAMA Internal Medicine. Approximately 0.3% of the population are carriers of a genetic mutation that has a large effect on cancer risk, accounting for about 5–10% of all cancers. Gx™ InhCa analysis 39 genes associated with major types of cancers, offering an effective tool for cancer risk screen and diagnosis.  

2300 Lifeexp0509 Current 05082017


The testing Provides:

  • Diagnosis of clinical condition
  • Assess cancer susceptibility
  • Identification of at-risk family members
  • Guidance for disease prognosis
  • Implications for therapeutic drugs

Candidates for Gx™ InhCa Testing

  • Patient with a family history of cancers
  • Patients who are at risk for other cancers
  • Patients with pre-cancer conditions 

Flexible Options to Select Testing for a Subset of 39 Gx™ InhCa Genes:

39 Genes Sampled

Gx™ BrCa1/2: BRCA1BRCA2

Gx™ BrOvCa:  ATMBRCA1BRCA2BRIP1CDH1MLH1MSH2

              MSH6PALB2PTENRAD51CRETSTK11TP53VHL

Gx™ CRCa:     APC,  BMPR1A, CDH1, EPCAM,  MLH1MSH2

                      MSH6MUTYH, PTEN, PMS2, SMAD4, STK11